Cardiological society of India position statement on COVID-19 and heart failure

Harikrishnan, S.; Mohanan, P.P.; Chopra, Vijay; Roy, Ambuj; Ganapathi, Sanjay; Bansal, Manish; Chakraborty, Rajarshi; Chandra, Sharad; Chattarjee, S. S.; Chopra, HK; Mathew, Cibu; Deb, Pradip Kumar; Goyal, Ankita; Goswami, Kalyan; Gupta, Rakesh; Guha, Santanu; Gupta, Varun; Hasija, P.K.; Wardhan, Harsh; Abdullakutty, Jabir; Jayagopal, P.B.; Kahali, Dhiman; Katyal, V K; Kerkar, P. G.; Khanna, Narendra N.; Majumder, Biswajit; Mandal, Manoranjan; Meena, Chandra Bhan; Naik, Nitish; Narain, VarunShankar; Pathak, Lekha; Ray, Saumitra; Roy, Debabrata; Routray, Satyanarayan; Sarma, Dipak Kumar; Shanmugasundaram, Saseendar; Singh, Bhanupriya; Tyagi, Sanjay; Venugopal, K.; Wander, GS; Yadav, Rakesh Kumar; Das, Mrinal Kanti

doi:10.1016/j.ihj.2020.04.012

Cited by 20 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heart failure is postulated to occur in COVID‐19 patients due to the severe immune system over‐reaction resulting in cytokine storm. The virus downregulates the angiotensin‐converting enzyme 2 (ACE2), leading to increased levels of Angiotensin II causing increased inflammation, hypertension, and thrombosis 21 . As further data becomes available, the mechanism of heart failure in COVID‐19 patients will become clearer and help provide a standard approach to its treatment.…”

Section: Resultsmentioning

confidence: 99%

Cardiac manifestations in COVID‐19 patients—A systematic review

et al. 2020

View full text Add to dashboard Cite

Objectives The coronavirus disease‐2019 (COVID‐19) pandemic has resulted in the worst global pandemic of our generation, affecting 215 countries with nearly 5.5 million cases. The association between COVID‐19 and the cardiovascular system has been well described. We sought to systematically review the current published literature on the different cardiac manifestations and the use of cardiac‐specific biomarkers in terms of their prognostic value in determining clinical outcomes and correlation to disease severity. Methods A systematic literature review across PubMed, Cochrane database, Embase, Google Scholar, and Ovid was performed according to PRISMA guidelines to identify relevant articles that discussed risk factors for cardiovascular manifestations, cardiac manifestations in COVID‐19 patients, and cardiac‐specific biomarkers with their clinical implications on COVID‐19. Results Sixty‐one relevant articles were identified which described risk factors for cardiovascular manifestations, cardiac manifestations (including heart failure, cardiogenic shock, arrhythmia, and myocarditis among others) and cardiac‐specific biomarkers (including CK‐MB, CK, myoglobin, troponin, and NT‐proBNP). Cardiovascular risk factors can play a crucial role in identifying patients vulnerable to developing cardiovascular manifestations of COVID‐19 and thus help to save lives. A wide array of cardiac manifestations is associated with the interaction between COVID‐19 and the cardiovascular system. Cardiac‐specific biomarkers provide a useful prognostic tool in helping identify patients with the severe disease early and allowing for escalation of treatment in a timely fashion. Conclusion COVID‐19 is an evolving pandemic with predominate respiratory manifestations, however, due to the interaction with the cardiovascular system; cardiac manifestations/complications feature heavily in this disease, with cardiac biomarkers providing important prognostic information.

show abstract

Section: Resultsmentioning

confidence: 99%

Cardiac manifestations in COVID‐19 patients—A systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The exact mechanism of cardiac injury due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been difficult to confirm ( 7 , 12 ), although some autopsy studies have showed direct myocyte involvement or secondary injury from the profound inflammatory response invoked by SARS-CoV-2 ( 7 , 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Elevated Extracellular Volume Fraction and Reduced Global Longitudinal Strains in Participants Recovered from COVID-19 without Clinical Cardiac Findings

Xiao-hu¹,

Wang

Zhao

et al. 2021

Radiology

View full text Add to dashboard Cite

Disclosures of Conflicts of Interest: X.L. disclosed no relevant relationships. H.W. disclosed no relevant relationships. R.Z. disclosed no relevant relationships. T.W. disclosed no relevant relationships. Y.Z. disclosed no relevant relationships. Y.Q. disclosed no relevant relationships. B.L. disclosed no relevant relationships. Y.Y. disclosed no relevant relationships. Y.H. disclosed no relevant relationships.

show abstract

“…The management of myocardial dysfunction in COVID-19 leading to HF is similar to other forms of HF. Optimization of fluid balance, monitoring of electrolytes and renal function, and early use of the cardiac catheterization laboratory and invasive monitoring all play important roles in managing COVID patients with HF [58].…”

Section: Myocardial Damagementioning

confidence: 99%

COVID-19 Pandemic: Cardiovascular Complications and Future Implications

Bandyopadhyay

Akhtar

Hajra

et al. 2020

Am J Cardiovasc Drugs

108

100

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a global pandemic with the highest number of affected individuals in the modern era. Not only is the infection inflicting significant morbidity and mortality, but there has also been a significant strain to the health care system and the economy. COVID-19 typically presents as viral pneumonia, occasionally leading to acute respiratory distress syndrome (ARDS) and death. However, emerging evidence suggests that it has a significant impact on the cardiovascular (CV) system by direct myocardial damage, severe systemic inflammatory response, hypoxia, right heart strain secondary to ARDS and lung injury, and plaque rupture secondary to inflammation. Primary cardiac manifestations include acute myocarditis, myocardial infarction, arrhythmia, and abnormal clotting. Several consensus documents have been released to help manage CV disease during this pandemic. In this review, we summarize key cardiac manifestations, their management, and future implications. Dhrubajyoti Bandyopadhyay, Adrija Hajra and Srihari S. Naidu contributed equally.

show abstract

Cardiological society of India position statement on COVID-19 and heart failure

Cited by 20 publications

References 25 publications

Cardiac manifestations in COVID‐19 patients—A systematic review

Cardiac manifestations in COVID‐19 patients—A systematic review

Elevated Extracellular Volume Fraction and Reduced Global Longitudinal Strains in Participants Recovered from COVID-19 without Clinical Cardiac Findings

COVID-19 Pandemic: Cardiovascular Complications and Future Implications

Contact Info

Product

Resources

About